tirzepatide and crohn's Patients with stable inflammatory bowel disease (IBD) comorbid obesity and/or diabetes who started GLP-1 receptor agonists (semaglutide or tirzepatide) alongside ongoing treatment did not have a lower risk for the relapse Crohn's and Mounjaro: Safety, Risks

The findings illustrate a recurring observation in IGF-1 LR3 research: mass-level effects do not necessarily translate to functional recovery, and delivery kinetics appear to be a critical variable in study outcomes

It functions by mimicking the GLP-1 hormone to lower blood sugar levels, suppress appetite, and slow gastric emptying

Integrating Cagrilintide Into Professional Practice For fitness instructors, health coaches, medispa professionals , and other wellness practitioners, understanding cagrilintide dosing provides valuable knowledge even if direct prescribing isn't within their scope of practice

Congratulations to Eli Lilly and the broader obesity treatment community